CA17140 Related Publications

This page lists international publications related to CA17140 which acknowledge the Action but cannot be classified as Action papers






  • Giesen B, Nickel AC, Barthel J, Kahlert UD, Janiak C. Augmented Therapeutic Potential of Glutaminase Inhibitor CB839 in Glioblastoma Stem Cells Using Gold Nanoparticle Delivery. Pharmaceutics. 2021;13:295 (https://doi.org/10.3390/pharmaceutics13020295)


  •  Tiwari AP, Thorat ND, Pricl S, Patil RM, Rohiwal S, Townley H. Bioink: a 3D-bioprinting tool for anticancer drug discovery and cancer management. Drug Discov Today. 2021;26(7):1574-1590. Copyright (C) Elsevier B.V. (https://doi.org/10.1016/j.drudis.2021.03.010).

  • Khot VM, Salunkhe AB, Pricl S, Bauer J, Thorat ND, Townley H. Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance. Drug Discov Today. 2021;26(3):724-739 Copyright (C) Elsevier B.V. (https://doi.org/110.1016/j.drudis.2020.12.016)

  • Aulic S, Marson D, Laurini E, Skoko N, Fermeglia M, Pricl S. Regulatory, safety, and toxicological concerns of nanomaterials with their manufacturing issues. In Nano-pharmacokinetics and theranostics: advancing cancer therapy, Nanasaheb D. Thorat and Nitesh Kumar Editors, Academic Press. Chapter 16, pp. 93-115 (2021). Copyright (C) 2020 Elsevier B.V.








 

IMPORTANT NOTICE: CA17140 publications must report the following official sentence in the acknowledgment section:

This article/publication is based upon work from COST Action CA 17140 "Cancer Nanomedicine from the Bench to the Bedside" supported by COST (European Cooperation in Science and Technology).

 

All applicants must carefully read the funding rules detailed on the COST website and acknowledge COST as a funding source. The acknowledgment shall follow the COST guidelines on visual identity.

Visual identity - COST – available here

European Cooperation in Science and Technology (COST) logo
EU flag logo

Funded by the Horizon 2020 Framework Programme
of the European Union